Stockwatch: J&J Earnings Show Benefits Of Diversity In Coronavirus
Group’s First-Quarter Results Likely To Echo Throughout 2020
Amarin and J&J opened the first-quarter 2020 earnings season. Amarin’s financial report was a mere whisper compared with J&J’s sonic boom of better-than-expected Q1 financials. Nonetheless, J&J’s reduced guidance and divisional effects will echo through the sector and the year.
You may also be interested in...
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?